GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Today
—
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Akums Drugs and Pharmaceuticals Ltd
Akums subsidiary's INR 3.59 Crore penalty set aside
REGULATORY ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Jul 2026, 06:04 PM IST  ·  BSE ID: dddf0a30-ff9a-4e3b-a56d-177033c0dd54
View Original BSE Filing (PDF)
💡
In Simple Terms
A penalty of INR 3.59 Crore against a subsidiary has been cancelled by a tax appeal authority.
🤖 AI Summary
  • Maxcure Nutravedics Limited's INR 3,59,10,000 penalty was set aside by Gujarat's First Appellate Authority.
  • The penalty was imposed by the Deputy Commissioner of State Tax, Ahmedabad, Gujarat.
  • The penalty was related to a shipping address error on an October 2025 invoice and e-way bill.
  • The company confirms no financial impact on Akums Drugs and Pharmaceuticals Limited.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Penalty Amount Set Aside
3,59,10,000
Penalty Authority
Deputy Commissioner of State Tax, Gujarat
Appellate Authority Order Date
03rd July, 2026
🏢 How This Affects the Company
📈
Business Impact
This development resolves a past tax dispute for the subsidiary, removing a previous financial encumbrance.
💰
Financial Impact
The setting aside of the penalty means the company will not incur the financial outflow of INR 3,59,10,000.
⚙️
Operational Impact
Operational processes related to invoicing and shipping address accuracy will continue as standard.
⚠️
Risk Impact
This action reduces past regulatory and financial risk associated with the penalty for the subsidiary.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding this regulatory update.
👤
Who Is Affected
All shareholders are informed of the resolution of a penalty concerning the company's wholly-owned subsidiary.
🔍
Management Signal
Management's proactive pursuit of the appeal and successful resolution signals effective handling of regulatory matters.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Company's next quarterly results filing for financial updates.
Any further regulatory communications from tax authorities.
Subsidiary's operational performance and compliance metrics.
LOW RISK This filing represents a resolution, not an escalation, of a past tax-related matter.
💡 Investor Takeaway
Akums' subsidiary Maxcure Nutravedics Limited had its INR 3,59,10,000 penalty cancelled by Gujarat's First Appellate Authority, confirming no financial impact on the company.
⚖️ Strengths & Concerns

✅ Positives

  • Penalty of INR 3,59,10,000 imposed on subsidiary Maxcure Nutravedics Limited has been set aside.
  • No financial impact on the company resulting from the penalty being set aside.
❓ Frequently Asked Questions
What penalty was imposed on Akums' subsidiary, Maxcure Nutravedics Limited?
A penalty of INR 3,59,10,000 was initially imposed on Maxcure Nutravedics Limited.
Who set aside the penalty on Maxcure Nutravedics Limited?
The First Appellate Authority, Ahmedabad, Gujarat, set aside the penalty via orders dated 03rd July, 2026.
What was the reason for the penalty?
The penalty was imposed due to a shipping address being mistakenly entered incorrectly in an invoice and e-way bill of October 2025.
What is the financial impact of this decision on Akums Drugs and Pharmaceuticals Limited?
The company has confirmed that there will be no financial impact on Akums Drugs and Pharmaceuticals Limited.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.